Echocardiography, Spirometry, and Systemic Acute-Phase Inflammatory Proteins in Smokers with COPD or CHF: An Observational Study
Open Access
- 11 November 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (11), e80166
- https://doi.org/10.1371/journal.pone.0080166
Abstract
Chronic obstructive pulmonary disease (COPD) and chronic heart failure (CHF) may coexist in elderly patients with a history of smoking. Low-grade systemic inflammation induced by smoking may represent the link between these 2 conditions. In this study, we investigated left ventricular dysfunction in patients primarily diagnosed with COPD, and nonreversible airflow limitation in patients primarily diagnosed with CHF. The levels of circulating high-sensitive C-reactive protein (Hs-CRP), pentraxin 3 (PTX3), interleukin-1β (IL-1 β), and soluble type II receptor of IL-1 (sIL-1RII) were also measured as markers of systemic inflammation in these 2 cohorts. Patients aged ≥50 years and with ≥10 pack years of cigarette smoking who presented with a diagnosis of stable COPD (n=70) or stable CHF (n=124) were recruited. All patients underwent echocardiography, N-terminal pro-hormone of brain natriuretic peptide measurements, and post-bronchodilator spirometry. Plasma levels of Hs-CRP, PTX3, IL-1 β, and sIL-1RII were determined by using a sandwich enzyme-linked immuno-sorbent assay in all patients and in 24 healthy smokers (control subjects). Although we were unable to find a single COPD patient with left ventricular dysfunction, we found nonreversible airflow limitation in 34% of patients with CHF. On the other hand, COPD patients had higher plasma levels of Hs-CRP, IL1 β, and sIL-1RII compared with CHF patients and control subjects (p < 0.05). None of the inflammatory biomarkers was different between CHF patients and control subjects. In conclusion, although the COPD patients had no evidence of CHF, up to one third of patients with CHF had airflow limitation, suggesting that routine spirometry is warranted in patients with CHF, whereas echocardiography is not required in well characterized patients with COPD. Only smokers with COPD seem to have evidence of systemic inflammation.This publication has 33 references indexed in Scilit:
- Pentraxin‐3 in chronic heart failure: the CORONA and GISSI‐HF trialsEuropean Journal of Heart Failure, 2012
- ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESCEuropean Heart Journal, 2012
- "GOLD or lower limit of normal definition? a comparison with expert-based diagnosis of chronic obstructive pulmonary disease in a prospective cohort-study"Respiratory Research, 2012
- COPD is associated with reduced pulmonary interstitial expression of pentraxin-3European Respiratory Journal, 2011
- Increase of plasma IL-9 and decrease of plasma IL-5, IL-7, and IFN-γ in patients with chronic heart failureJournal of Translational Medicine, 2011
- The prognostic importance of lung function in patients admitted with heart failureEuropean Journal of Heart Failure, 2010
- Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiologyEuropean Journal of Heart Failure, 2009
- Chronic obstructive pulmonary disease in heart failure. Prevalence, therapeutic and prognostic implicationsAmerican Heart Journal, 2008
- Profiling serum biomarkers in patients with COPD: associations with clinical parametersThorax, 2007
- Circulating concentrations of proinflammatory cytolcines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathyThe American Journal of Cardiology, 1996